5-phenyl-N-propan-2-yl-1,2-oxazole-3-carboxamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 5-phenyl-N-propan-2-yl-1,2-oxazole-3-carboxamide
• 化学式: C₁₃H₁₄N₂O₂
• mdl: MFCD06010753
• 分子量: 230.26
• InChiKey: IJRFYRIYWKYKTC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Compounds, compositions, and methods for increasing CFTR activity
  申请人：Proteostasis Therapeutics, Inc.

  公开号：US10738040B2

  公开（公告）日：2020-08-11

  The present disclosure features disclosed compounds which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound.

  本公开内容的特征是所公开的化合物可提高在人支气管上皮细胞（hBE）中测定的囊性纤维化跨膜传导调节剂（CFTR）活性。本公开内容还包括治疗与 CFTR 活性降低相关的疾病或与蛋白稳态功能障碍相关的疾病的方法，包括向受试者施用有效量的公开化合物。
• COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY
  申请人：Proteostasis Therapeutics, Inc.

  公开号：US20190308960A1

  公开（公告）日：2019-10-10

  The present disclosure features disclosed compounds which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound.